An Adaptive Phase 2 Trial to Evaluate PL8177 in Hospitalized, Moderate or Severe COVID-19 Adult Subjects with Hypoxemic Respiratory Failure With or Without Mild Acute Respiratory Distress Syndrome (ARDS)
Latest Information Update: 06 Oct 2020
At a glance
- Drugs PL 8177 (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Respiratory insufficiency
- Focus Therapeutic Use
- Sponsors Palatin Technologies
Most Recent Events
- 28 Sep 2020 According to a Palatin Technologies media release, considering the risk and uncertainty of conducting COVID-19 clinical studies, the start of this PL8177 clinical study is subject to receiving external funding and operational support. The Company is in the process of applying to government programs that provide such support.
- 28 Sep 2020 According to a Palatin Technologies media release, Palatin is advancing its COVID-19 development plan and is conducting all the required activities needed to file an IND and begin clinical studies with PL8177 in COVID-19 patients. These activities will be completed in the fourth calendar quarter of 2020, allowing the Company to potentially file an IND with the FDA and initiate this clinical study of PL8177 for the treatment of COVID-19 patients early in the first calendar quarter of 2021.
- 28 Jun 2020 New trial record